ADCs: the next generation of targeted therapies
Drug Discovery World
SEPTEMBER 25, 2024
Antibody drug conjugates (ADCs) are among the hottest properties in pharma, powerful anticancer drugs that target tumours and deliver a lethal payload that destroys them, while leaving healthy tissues untouched. But there’s much more to come from this technology. DDW’s Megan Thomas explores the topic and speaks with experts in the industry. Early days of ADC drug development The first ADC was approved around the turn of the century, with Pfizer’s Mylotarg (gemtuzumab ozogamicin) becoming the fi
Let's personalize your content